FindTrial
Sign In

PI3K inhibitor BYL719

DRUG2 trials

Sponsors

Vanderbilt-Ingram Cancer Center, Northwestern University

Conditions

Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerHER2-positive Breast CancerInvasive Ductal Breast CarcinomaProgesterone Receptor-positive Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer

Phase 1

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Active, not recruitingNCT01791478
Vanderbilt-Ingram Cancer CenterEstrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma +3
Start: 2013-04-30End: 2025-02-28Updated: 2024-07-23
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
CompletedNCT02038010
Northwestern UniversityHER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer +3
Start: 2014-05-21End: 2017-05-20Updated: 2020-06-29

Related Papers

Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy.
Journal of Clinical Oncology2017-05-2016 citations
Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.
Journal of Clinical Oncology2016-05-202 citations
Abstract CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer
Cancer Research2015-08-013 citations
SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2– metastatic breast cancer (MBC).
Journal of Clinical Oncology2014-05-203 citations
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
Journal of Clinical Oncology2014-05-201 citations